-
Uncategorized2 months ago
StockWatch: Revolution’s Phase III Pancreatic Cancer Data Dazzles Investors, Analysts
Pancreatic cancer is one of the most difficult cancers to treat, with an overall five-year survival rate of 13%, according to the American Cancer Society, stretching...
-
Uncategorized2 months agoSTAT+: The race to catch KRAS, pancreatic cancer’s ‘greasy ball,’ and create the most promising drug in decades
Leanna Stokes had gotten into the habit of asking her oncologist what might be next for her treatment, and for good reason. Stokes, a 36-year-old gymnastics...
-
Uncategorized2 months ago10x Genomics Unveils Atera Spatial Platform at AACR Meeting
The genomics community’s long wait for 10x Genomics’ highly anticipated news is finally over. On Saturday night, at the Hard Rock Café Hotel in San Diego—across...
-
Uncategorized2 months ago
Three gene therapy pioneers just won the Breakthrough Prize. This is their story
A trio of scientists behind the first gene therapy approved in the United States have been awarded a Breakthrough Prize in Life Sciences. It’s arguably one...
-
Uncategorized2 months agoHow Trump is pushing psychedelics reform through the health agencies
WASHINGTON — President Trump moved on Saturday to “reverse the crisis of serious mental illness in America” by boosting access to psychedelic drugs in clinical settings....
-
Uncategorized2 months agoOptimism for Trump’s CDC pick is tempered by questions about RFK Jr.’s role
The nomination of a new leader for the Centers for Disease Control and Prevention — one who has scientific credentials and no public ties to the...
-
Uncategorized2 months ago
RevMed’s stunning success; FDA to reclassify peptides; and more
RevMed’s stunning success; FDA to reclassify peptides; and more
-
Uncategorized2 months ago
AACR: FDA vet Pazdur bemoans state of agency, warns of political influence and ‘sense of anxiety’
Asked by Fierce if he’d consider returning to the FDA, Pazdur said he wouldn’t serve again under the Trump administration “for obvious reasons.”
-
Uncategorized2 months agoUCB, betting on seizure cell therapy, to buy Neurona for up to $1.2B
The acquisition helps diversify UCB’s small molecule-centric arsenal of seizure treatments with a potentially one-off therapy in early testing for a hard-to-treat form of a common...
-
Uncategorized2 months ago
Tunneling Neurons in Adult Bird Brains Provide New Insights into Neurogenesis
Despite its small size—it could sit in the palm of your hand—the zebra finch is a remarkable learner. A songbird native to Australia, it’s renowned for...
